Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Pilot study of topotecan and high-dose cyclophosphamide for resistant pediatric solid tumors.

Kushner BH, Kramer K, Meyers PA, Wollner N, Cheung NK.

Med Pediatr Oncol. 2000 Nov;35(5):468-74.

PMID:
11070479
2.

Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study.

Saylors RL 3rd, Stine KC, Sullivan J, Kepner JL, Wall DA, Bernstein ML, Harris MB, Hayashi R, Vietti TJ; Pediatric Oncology Group.

J Clin Oncol. 2001 Aug 1;19(15):3463-9.

PMID:
11481351
3.

Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: a Pediatric Oncology Group Study.

Saylors RL 3rd, Stewart CF, Zamboni WC, Wall DA, Bell B, Stine KC, Vietti TJ.

J Clin Oncol. 1998 Mar;16(3):945-52.

PMID:
9508177
4.

Phase I study of combination topotecan and carboplatin in pediatric solid tumors.

Athale UH, Stewart C, Kuttesch JF, Moghrabi A, Meyer W, Pratt C, Gajjar A, Heideman RL.

J Clin Oncol. 2002 Jan 1;20(1):88-95.

PMID:
11773158
5.
6.
7.

Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors.

Hunold A, Weddeling N, Paulussen M, Ranft A, Liebscher C, Jürgens H.

Pediatr Blood Cancer. 2006 Nov;47(6):795-800.

PMID:
16411206
8.

Serial intense chemotherapy combining topotecan, etoposide, carboplatin and cyclophosphamide (TECC) followed by autologous hematopoietic stem cell support in patients with high risk soft tissue sarcoma (STS).

Bernbeck B, Bahci S, Meisel R, Troeger A, Schönberger S, Laws HJ, Kramm C, Wessalowski R, Koscielniak E, Dilloo D, Göbel U.

Klin Padiatr. 2007 Nov-Dec;219(6):318-22.

PMID:
18050041
9.

Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas.

Hawkins DS, Felgenhauer J, Park J, Kreissman S, Thomson B, Douglas J, Rowley SD, Gooley T, Sanders JE, Pendergrass TW.

Cancer. 2002 Sep 15;95(6):1354-65.

10.

Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.

Hagemeister FB.

Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. Epub 2002 Apr 12. Review.

PMID:
12042984
11.

Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma.

Kushner BH, Kramer K, Modak S, Qin LX, Cheung NK.

Cancer. 2010 Jun 15;116(12):3054-60. doi: 10.1002/cncr.25232.

12.

Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high-risk sarcomas: the St. Jude Children's Research Hospital experience.

Navid F, Santana VM, Billups CA, Merchant TE, Furman WL, Spunt SL, Cain AM, Rao BN, Hale GA, Pappo AS.

Cancer. 2006 Apr 15;106(8):1846-56.

13.

Feasibility of four consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy: results of a collaborative study.

Strother D, Ashley D, Kellie SJ, Patel A, Jones-Wallace D, Thompson S, Heideman R, Benaim E, Krance R, Bowman L, Gajjar A.

J Clin Oncol. 2001 May 15;19(10):2696-704.

PMID:
11352962
14.

Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas: pilot study for the upcoming European Rhabdomyosarcoma Protocol.

Casanova M, Ferrari A, Bisogno G, Merks JH, De Salvo GL, Meazza C, Tettoni K, Provenzi M, Mazzarino I, Carli M.

Cancer. 2004 Oct 1;101(7):1664-71.

15.

Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease.

Josting A, Rudolph C, Reiser M, Mapara M, Sieber M, Kirchner HH, Dörken B, Hossfeld DK, Diehl V, Engert A; Participating Centers.

Ann Oncol. 2002 Oct;13(10):1628-35.

16.

Repetitive high-dose topotecan, carboplatin, and paclitaxel with peripheral blood progenitor cell support in previously untreated ovarian cancer: results of a Phase I study.

Prince HM, Rischin D, Quinn M, Allen D, Planner R, Neesham D, Gates P, Davison J.

Gynecol Oncol. 2001 May;81(2):216-24.

PMID:
11330952
17.

Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.

Mangel J, Buckstein R, Imrie K, Spaner D, Crump M, Tompkins K, Reis M, Perez-Ordonez B, Deodhare S, Romans R, Pennell N, Robinson JB, Hewitt K, Richardson P, Lima A, Pavlin P, Berinstein NL.

Semin Oncol. 2002 Feb;29(1 Suppl 2):56-69. Review.

PMID:
11842390
18.

Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a phase-II trial.

Simon T, Längler A, Harnischmacher U, Frühwald MC, Jorch N, Claviez A, Berthold F, Hero B.

J Cancer Res Clin Oncol. 2007 Sep;133(9):653-61. Epub 2007 May 4.

PMID:
17479288
19.

A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors.

Seiden MV, Ng SW, Supko JG, Ryan DP, Clark JW, Lynch T, Huang KC, Kwiatkowski D, Skarin A, Eder JP Jr.

Clin Cancer Res. 2002 Mar;8(3):691-7.

20.

Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children's Oncology Group study.

Hawkins DS, Bradfield S, Whitlock JA, Krailo M, Franklin J, Blaney SM, Adamson PC, Reaman G.

Pediatr Blood Cancer. 2006 Nov;47(6):790-4.

PMID:
16435380
Items per page

Supplemental Content

Write to the Help Desk